Platinum-Based Combination Therapy: Molecular Rationale, Current Clinical Uses, and Future Perspectives

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Platinum-based chemotherapy is a cornerstone of cancer treatment.
• Clinical use is hampered by acquired drug resistance and significant toxicities.
• Combination therapy is emerging as a key strategy to enhance outcomes.

Purpose of the Study:

• To review the mechanistic basis for combining platinum drugs with other anticancer agents.
• To guide the development of novel platinum-based combination regimens.
• To inspire the design of multitargeting platinum drugs that overcome resistance and toxicity.

Main Methods:

• Literature review focusing on mechanistic studies of platinum drug combinations.
• Analysis of preclinical and clinical data on combination therapies.
• Exploration of strategies to overcome platinum resistance and reduce side effects.

Main Results:

• Combination therapy, particularly with checkpoint inhibitors, shows promise in improving therapeutic efficiency.
• Understanding combination mechanisms is crucial for optimizing treatment strategies.
• Novel platinum drug designs are needed to address current limitations.

Conclusions:

• Platinum-based combination regimens represent a leading strategy to improve cancer chemotherapy.
• Further research into combination mechanisms will drive the development of more effective treatments.
• Developing multitargeting platinum drugs is essential for overcoming clinical challenges.